Lb Pharmaceuticals (LBRX) Total Current Liabilities (2024 - 2026)

Lb Pharmaceuticals has reported Total Current Liabilities for 3 years, with the latest figure at $10.9 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities changed N/A year-over-year to $10.9 million; the trailing twelve-month figure through Mar 2026 stood at $10.9 million (changed N/A YoY), and the FY2025 full-year result was $7.4 million, down 8.23% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $10.9 million, up from $7.4 million in the prior quarter.
• The five-year high for Total Current Liabilities was $10.9 million in Q1 2026, with the low at $6.6 million in Q3 2025.
• Average Total Current Liabilities over 3 years is $8.3 million, with a median of $7.8 million recorded in 2024.
• Peak annual rise in Total Current Liabilities reached 8.23% in 2025, while the deepest fall reached 8.23% in 2025.
• Tracing LBRX's Total Current Liabilities over 3 years: stood at $8.1 million in 2024, then declined by 8.23% to $7.4 million in 2025, then soared by 46.55% to $10.9 million in 2026.
• The last three Total Current Liabilities figures came in at $10.9 million (Q1 2026), $7.4 million (Q4 2025), and $6.6 million (Q3 2025), per Business Quant data.

Peer Comparison